The World Health Organisation cites caries as the most prevalent disease in mankind, affecting over ninety-eight percent of all humans in their lifetime.
Treating caries on a global scale and the serious illnesses that result from untreated caries (which happens a lot because many people are very fearful of going to the dentist) costs over 300 billion euro's annually, sucking up over five percent of the global health budget.
Reminova can change this, with our painless reparative treatment known as EAER.
It reverses the effects of caries attack and repairs enamel.
Its an essentially painless process, and the repaired areas of the enamel are almost identical to natural enamel, as we use the same natural building block of tooth enamel, which are calcium and phosphate groups.
This treatment can be important in reducing overall dental costs, and reducing the impact of dental caries on society.
Having a painless treatment can increase dental attendance, as throughout most countries of Europe, around one in four of the population do not attend a dentist regularly or at all.
Our Feasibility Study objective was to analyse and evidence the commercial potential and opportunity that this treatment offers. In answering critical technical uncertainties we have been able to sharpen the commercial value proposition.
This will enable our Company to attract further investment and expedite commercial discussions.
Our Company has a number of activities underway which in 2017 will build on the findings of the Phase 1 Feasibility Study.